Delorean Corporation Ltd (ASX:DEL) Welcomes Regulatory Reforms for Renewable Gas
Delorean Corporation Ltd (ASX:DEL) announces regulatory reforms that enhance its renewable gas projects and biomethane market viability in Australia.
Xero Limited (ASX:XRO) Acquires Melio to Accelerate Global Growth
Xero Limited (ASX:XRO) acquires Melio to enhance its US operations and accelerate global growth, supported by a significant capital raise.
Brightstar Resources (ASX:BTR) Reports Significant Results from Sandstone Hub Drilling
Brightstar Resources (ASX:BTR) reports further significant drilling results at Sandstone Hub, enhancing its Mineral Resource Estimate.
Kip McGrath Education Centres (ASX:KME) Provides FY25 Trading Update and Announces Exit from USA Business
Kip McGrath (ASX:KME) provides FY25 trading update, exits USA business, and announces new CEO Melinda Smith.
GBM Resources Limited (ASX:GBZ) Announces $13 Million Placement and Board Restructure
GBM Resources (ASX:GBZ) secures $13M through placement, repays debt, and restructures Board to enhance Drummond Basin gold assets.
Eureka Group Holdings Limited (ASX:EGH) Appoints Simon Owen as Managing Director
Eureka Group Holdings Limited (ASX:EGH) appoints Simon Owen as Managing Director, enhancing leadership for growth and market position.
Biotron Limited (ASX:BIT) Completes Safety Study for HBV Drug
Biotron Limited (ASX:BIT) completes safety study for its HBV drug, advancing to efficacy testing in animal models.
Dexus (ASX:DXS) Announces Portfolio Valuation Increase and Estimated Distribution
Dexus (ASX:DXS) reports a $55M portfolio valuation increase and announces an 18.0 cents per security distribution for H1 FY25.
Maggie Beer Holdings (ASX:MBH) Completes Sale of Paris Creek Farms
Maggie Beer Holdings (ASX:MBH) completes the sale of Paris Creek Farms, focusing on its core growth assets.
PYC Therapeutics (ASX:PYC) Aligns with FDA on Registrational Trial Design for RP11 Treatment
PYC Therapeutics (ASX:PYC) aligns with the FDA on registrational trial design for its RP11 treatment, advancing VP-001 to Phase 2/3 studies.